Compare BridgeBio Pharma Inc (BBIO) vs eBay Inc (EBAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs eBay Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while eBay Inc trades at $106.11 (market cap $47.93B). The key difference: eBay Inc is far larger — about 2.9× BridgeBio Pharma Inc's market cap, and eBay Inc pays a 1.15% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | EBAY | |
|---|---|---|
Market Cap | $16.61B | $47.93B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $118.96 |
52-Week Low | $47.29 | $79.41 |
Enterprise Value | $18.16B | $51.75B |
Volume | — | 5,186,418 |
Dividend Yield | — | 1.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
EBAY trades at $111.98, up 1.67% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals, including a net income margin of 18.57% and ROE of 47.38%, supported by revenue growth to $11.10B in 2025. Recent news highlights potential partnership talks with GameStop after a withdrawn $56B bid, adding volatility but strategic interest.
Outlook is positive with a consensus price target of $119.85, indicating ~7% upside, driven by earnings momentum and focus category growth. Risks include competitive pressures in e-commerce and market sensitivity to merger speculation. Investors may find value in sustained profitability and analyst buy ratings, though monitor execution on guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About eBay Inc
eBay Inc. is a global commerce company. The Company's platforms are designed to enable sellers worldwide to organize and offer their inventory for sale and buyers to find and buy it. eBay's items can be new or used, plain or luxurious, commonplace or rare, trendy or one-of-a-kind.
Read more on EBAY →
